Personalized neoantigen vaccines show promise in activating immune responses and controlling tumors in kidney cancer patients. A phase 1 trial demonstrated neoantigen-specific T-cell responses and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback